Asset Details
Do you wish to reserve the book?
The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
Do you wish to request the book?
The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
2010
Overview
While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between adenocarcinomas (ACs) and SCCs is P63. It is a well-known marker of squamous differentiation, but surprisingly, its expression is not widely used for this purpose. Our goals in this study were (1) to further confirm our microarray data, (2) to analize the value of P63 immunohistochemistry (IHC) in reducing the number of large cell carcinoma (LCC) diagnoses in surgical specimens, and (3) to investigate the potential of P63 IHC to minimize the proportion of \"carcinoma NOS (not otherwise specified)\" in a prospective series of small tumor samples.
With these goals in mind, we studied (1) a tissue-microarray comprising 33 ACs and 99 SCCs on which we performed P63 IHC, (2) a series of 20 surgically resected LCCs studied for P63 and TTF-1 IHC, and (3) a prospective cohort of 66 small thoracic samples, including 32 carcinoma NOS, that were further classified by the result of P63 and TTF-1 IHC.
The results in the three independent cohorts were as follows: (1) P63 IHC was differentially expressed in SCCs when compared to ACs (p<0.0001); (2) half of the 20 (50%) LCCs were positive for P63 and were reclassified as SCCs; and (3) all P63 positive cases (34%) were diagnosed as SCCs.
P63 IHC is useful for the identification of lung SCCs.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
Biomarkers, Tumor - metabolism
/ Biopsy
/ Carcinoma, Squamous Cell - diagnosis
/ Carcinoma, Squamous Cell - metabolism
/ Carcinoma, Squamous Cell - pathology
/ Carcinoma, Squamous Cell - surgery
/ DNA-Binding Proteins - metabolism
/ Ethics
/ Humans
/ Membrane Proteins - metabolism
/ Oligonucleotide Array Sequence Analysis
/ Oncology
/ Prostate
/ Studies
/ Surgery
/ Thorax
/ Tumors
